CASES EU Insights Into Acute Myeloid Leukemia (AML)

Provide an overview of the current and evolving treatment landscape in adult patients with AML, in the frontline and relapsed/refractory settings Understand the need to risk-stratify AML patients to optimize treatment selection on the basis of currently approved agents. Review the clinical data to support use of these agents and optimal management of patients Through case-based discussions, understand the appropriate sequencing of available agents to maximize the clinical outcomes of AML patients

EU May 21, 2021

Faculty Chair

Adriano Venditti, MD

University of Rome Tor Vergata, Rome, Italy

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report


The meeting report will be based on the following topics

  • First-Line Treatment of AML
    Overview of current data
    Factors guiding first-line therapy
    Impact of age, cytogenetics, molecular markers, comorbidities, PS, and etiology (primary, therapy-related, myelodysplasia-related changes) on induction therapy selection
    Integration of novel agents approved and under investigation (FLT3 inhibitors, BCL2 inhibitors, Hedgehog pathway inhibitors, IDH1 inhibitors)
    Role of MRD
    Maintenance therapy
  • Management of Relapsed/Refractory AML and Promising Strategies
    Overview of current data
    Factors guiding second-line and subsequent therapy
    Biomarkers at relapse
    Patient age, timing of relapse (<12 months vs ≥12 months), and role of reinduction or HCT
    Targeted therapy for FLT3-positive, CD33-positive, and IDH1– or IDH2-positive patients


  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 15 hematologists from Spain, Italy and Germany

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.